Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Ianalumab

Ianalumab and the Changing Landscape of ITP Treatment - ITP Support Association
Aug 10, 2026, 13:36 | Voices
Ianalumab and the Changing Landscape of ITP Treatment - ITP Support Association
ITP Support Association shared a post on LinkedIn: "We asked Tung Le at Imperial College Hammersmith Hospital…
VAYHIT3: Durable 12-Month Responses with Ianalumab in Primary ITP
Jun 14, 2026, 11:55 | Blog
VAYHIT3: Durable 12-Month Responses with Ianalumab in Primary ITP
Primary immune thrombocytopenia (ITP) is an autoimmune disorder where low platelet counts increase bleeding risk.…
Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Dec 26, 2025, 08:16 | Science
Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn: "Good news…
Wolfgang Miesbach: From Daily Pills to Remission after Short‑Course Therapy in ITP
Dec 13, 2025, 20:23 | Science
Wolfgang Miesbach: From Daily Pills to Remission after Short‑Course Therapy in ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn: ”From Daily Pills to Remission…
An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Dec 13, 2025, 15:20 | Drugs
An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared on LinkedIn: ''Today, at…
VAYHIT2 Trial: Ianalumab’s Role in Enhancing ITP Treatment Outcomes
Aug 15, 2025, 14:23 | Drugs
VAYHIT2 Trial: Ianalumab’s Role in Enhancing ITP Treatment Outcomes
VAYHIT2 trial evaluated the combination of ianalumab and eltrombopag in patients with primary immune thrombocytopenia…
Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Aug 13, 2025, 10:08 | Drugs
Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared an announcement on LinkedIn:…
All: 7 Posts: 1 - 100
NewsFeed